Table 3.
Univariable associations of the composite embolic endpoint among LV thrombus (n = 155) and matched non-LV thrombus patients (n = 400)
| Hazard ratio (95% CI) | P value | |
|---|---|---|
| Age | 0.99 (0.96 – 1.01) | 0.35 |
| Male | 0.66 (0.32 – 1.36) | 0.26 |
| Body mass index | 0.96 (0.90 – 1.02) | 0.18 |
| Body surface area | 0.37 (0.11 – 1.23) | 0.11 |
| Hypertension | 0.85 (0.41 – 1.76) | 0.67 |
| Dyslipidemia | 1.78 (0.80 – 3.98) | 0.16 |
| Diabetes mellitus | 1.95 (0.94 – 4.02) | 0.07 |
| Tobacco use | 1.04 (0.50 – 2.14) | 0.92 |
| Atrial fibrillation or flutter | 0.47 (0.11 – 1.95) | 0.30 |
| Known coronary artery disease | 2.40 (1.15 – 5.02) | 0.020 |
| Recent myocardial infarction | 2.23 (0.86 – 5.82) | 0.10 |
| Cerebrovascular disease | 1.95 (0.80 – 4.76) | 0.14 |
| Peripheral vascular disease | 4.04 (1.74 – 9.41) | 0.001 |
| CHA2DS2-VASc score | 1.15 (0.93 – 1.43) | 0.19 |
| LV thrombus on CMR | 4.67 (2.26 – 9.62) | <0.001 |
| LVEF on CMR | 0.98 (0.95 – 1.00) | 0.10 |
| LVEDVI on CMR | 1.00 (0.99 –1.01) | 0.94 |
| LVESVI on CMR | 1.00 (0.99 – 1.01) | 0.68 |
| LV aneurysm on CMR | 3.45 (1.67 – 7.11) | <0.001 |
| Ischemic LGE on CMR | 2.57 (1.15 – 5.75) | 0.021 |
| Non-ischemic LGE on CMR | 0.62 (0.19 – 2.05) | 0.43 |
| Global LGE extent on CMR | 1.03 (1.00 – 1.05) | 0.019 |
| Aspirin after CMR | 2.12 (0.95 – 4.75) | 0.07 |
| Thienopyridine after CMR | 1.92 (0.90 – 4.07) | 0.09 |
| Anticoagulation after CMR | 2.84 (1.36 – 5.92) | 0.005 |
| Ischemic cardiomyopathy | 0.89 (0.50 – 1.59) | 0.70 |
CI = confidence interval; CMR = cardiovascular magnetic resonance; LGE = late gadolinium enhancement; LV = left ventricle; LVEDVI = left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVESVI = left ventricular end-systolic volume index